EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer

David Ventura iD, Philipp Schindler iD, Max Masthoff iD, Dennis Görlich, Matthias Dittmann, Walter Heindel iD, Michael Schäfers, Georg Lenz, Eva Wardelmann, Michael Mohr, Peter Kies, Annalen Bleckmann und 2 weitere

Cancers · 14.04.2023 · 15 (8) · 2297

DOI: 10.3390/cancers15082297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 14.04.2023. Verfasst von David Ventura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Muenster, 48149 Muenster, Germany. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open Access Publication Fund of the University of Muenster.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to evaluate the predictive and prognostic value of baseline 18F-FDG-PET-CT (PET-CT) radiomic features (RFs) for immune checkpoint-inhibitor (CKI)-based first-line therapy in advanced non-small-cell lung cancer (NSCLC) patients. In this retrospective study 44 patients were included. Patients were treated with either CKI-monotherapy or combined CKI-based immunotherapy–chemotherapy as first-line treatment. Treatment response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). After a median follow-up of 6.4 months patients were stratified into “responder” (n = 33) and “non-responder” (n = 11). RFs were extracted from baseline PET and CT data after segmenting PET-positive tumor volume of all lesions. A Radiomics-based model was developed based on a Radiomics signature consisting of reliable RFs that allow classification of response and overall progression using multivariate logistic regression. These RF were additionally tested for their prognostic value in all patients by applying a model-derived threshold. Two independent PET-based RFs differentiated well between responders and non-responders. For predicting response, the area under the curve (AUC) was 0.69 for “PET-Skewness” and 0.75 predicting overall progression for “PET-Median”. In terms of progression-free survival analysis, patients with a lower value of PET-Skewness (threshold < 0.2014; hazard ratio (HR) 0.17, 95% CI 0.06–0.46; p < 0.001) and higher value of PET-Median (threshold > 0.5233; HR 0.23, 95% CI 0.11–0.49; p < 0.001) had a significantly lower probability of disease progression or death. Our Radiomics-based model might be able to predict response in advanced NSCLC patients treated with CKI-based first-line therapy.

Schlagwörter

Stichwörter der Autor:innen

FDG-PET-CTNSCLCPD-1PD-L1TPSartificial intelligenceimmune checkpoint inhibitionpembrolizumabradiomics

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Muenster, 48149 Muenster, Germany.
  • West German Cancer Center (WTZ), 48149 Muenster, Germany.
  • Clinic for Radiology, University and University Hospital Muenster, 48149 Muenster, Germany.
  • Institute of Biostatistics and Clinical Research, University of Muenster, 48149 Muenster, Germany.
  • Department of Medicine A-Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Muenster, 48149 Muenster, Germany.
  • Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, 48149 Muenster, Germany.

ORCID-Profile: David Ventura, Philipp Schindler, Max Masthoff, Walter Heindel, Wolfgang Roll, Georg Evers

Förderung

  • Open Access Publication Fund of the University of Muenster

Zitieren

APA

Ventura, D., Schindler, P., Masthoff, M., Görlich, D., Dittmann, M., Heindel, W., Schäfers, M., Lenz, G., Wardelmann, E., Mohr, M., Kies, P., Bleckmann, A., Roll, W., & Evers, G. (2023). Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer. Cancers, 15(8), 2297. https://doi.org/10.3390/cancers15082297

Vancouver

Ventura D, Schindler P, Masthoff M, Görlich D, Dittmann M, Heindel W, et al. Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer. Cancers. 2023;15(8):2297. doi:10.3390/cancers15082297

BibTeX
@article{Ventura2023,
  author = {Ventura, David and Schindler, Philipp and Masthoff, Max and Görlich, Dennis and Dittmann, Matthias and Heindel, Walter and Schäfers, Michael and Lenz, Georg and Wardelmann, Eva and Mohr, Michael and Kies, Peter and Bleckmann, Annalen and Roll, Wolfgang and Evers, Georg},
  title = {Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {8},
  pages = {2297},
  doi = {10.3390/cancers15082297}
}
Kostenlos starten →